Contact Information
AddressCancer Biology and Pharmacology, Genome Institute of Singapore,
60 Biopolis Street, 02-01, Genome, Singapore 138672
Qiang YU
Contact in UMOffice: E12-3032
Tel: (853)8822 4934
Ph.D.Cancer Pharmacology, Queen’s University, Kingston,
Ontario, Canada (1998)
M.Sc.Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (1991)
M.B.Qingdao University Medical College, China (1985)
2016-presentAdjunct Professor, Faculty of Health Sciences, University of Macau
2011-presentSenior Group Leader, Cancer Biology and Pharmacology, Genome Institute of Singapore
2011-presentAdjunct Professor, Department of Physiology, National University of Singapore
2011-presentAdjunct Professor, Cancer and Stem Cell Biology, DUKE-NUS
2006-2011Adjunct Associate Professor, Department of Physiology, National University of Singapore
2006-2011Group Leader, Cancer Biology and Pharmacology, Genome Institute of Singapore
2002-2006Senior Scientist and Principle Investigator, Cancer Biology and Pharmacology, Genome Institute of Singapore
2000-2002Visiting Fellow Advanced Technology Center National Cancer Institute Gaithersburg,
1998-2001International Fogarty Fellow Laboratory of Molecular Pharmacology, National Cancer Institute Bethesda, MD, USA
1991-1993Research Associate, Institute of Medical Sciences, Chinese Academy of Medical Sciences
Committee and Advisory Board
2011-presentEditorial Board, Frontiers Oncology
2008-presentAssociate Editor, Molecular Cancer (BioMed Central)
2007-presentEditorial Board, International Journal of Biochemistry and Cell Biology (Elsevier)
2005-2006Management Advisory Committe, Biopolis Life Science Library
Research Interest
  • Cancer therapeutics and drug discovery
  • Cancer signaling pathway modulation and drug resistance mechanisms
  • Cancer genomics and epigenetics for drug targets and biomarker discovery
Representative Publications
  • Wee ZN, Yatim SM, Kohlbauer VK, Feng M, Goh JY, Yi B, Lee PL, Zhang S, Wang PP, Lim E, Tam WL, Cai Y, Ditzel HJ, Hoon DS, Tan EY, Qiang Yu “IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel.” Nat Commun 2015 ; 6 : 8746
  • Feng M, Bao Y, Li Z, Li J, Gong M, Lam S, Wang J, Marzese DM, Donovan N, Tan EY, Hoon DS, Qiang Yu. “RASAL2 activates RAC1 to promote triple-negative breast cancer progression.” J Clin Invest , 2014 Dec;124(12):5291-304
  • Tan J, Li Z, Lee PL, Guan P, Aau M, Lee ST, Feng M, Lim CZ, Lee EY, Wee ZN, Lim YC, Karuturi RK, Yu Q. “PDK1 Signaling Towards PLK1-Myc Activation Confers Oncogenic Transformation and Tumor Initiating Cell Activation and Resistance to mTOR-targeted Therapy.” Cancer Discov 2013
  • Shuet Theng Lee1, Min Feng, Yong Wei, Zhimei Li, Yuanyuan Qiao1, Peiyong Guan, Meiyee Aau, Xia Jiang, Chew Hooi Wong, Kelly Huynh, Jinhua Wang, Juntao Li, K. Murthy Karuturi, Ern Yu Tan, Dave SB Hoon, Yibin Kang, Qiang Yu. Protein Tyrosine Phosphatase UBASH3B is Overexpressed in Triple-Negative Breast Cancer and Promotes Invasion and Metastasis. Proc Natl Acad Sci U S A, 2013 Jul 2;110(27):11121-6
  • Shuet Theng Lee, Zhimei Li, Zhenlong Wu, Meiyee Aau, Peiyong Guan, R.K. Murthy Karuturi, Yih Cherng Liou and Qiang Yu .”Context-Specific Regulation of NF-kB Target Gene Expression by EZH2 in Breast Cancers”. Molecular Cell , 43, 798–810, 2011
  • Jing Tan, Puay Leng Lee, Zhimei Li, Xia Jiang, Yaw Chyn Lim, Shing Chuan Hooi and Qiang Yu. B55β-associated PP2A complex controls PDK1-directed Myc signaling and modulates rapamycin sensitivity in colorectal cancer. Cancer Cell, 18:459-471, 2010
  • Xiaojing Yang, Min Feng, Xia Jiang, Zhenlong Wu, Meiyee AAu, Zhimei Li, and Qiang Yu. miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A. Genes & Development . 2009 23: 2388-2393
  • Xia Jiang, Jing Tan, Jingsong Li, Saul Kivimäe, Xiaojing Yang1 Li Zhuang, Puay Leng Lee, Mark TW. Chan, Lawrence Stanton, Edison T. Liu, Benjamin N.R.Cheyette and Qiang Yu. DACT3 is an epigenetic regulator of Wnt/β-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell. 13:529, 2008. PMID: 18538736
  • Jing Tan, Xiaojing Yang, Li Zhuang, Xia Jiang, Wei Chen, Puay Leng Lee, RK Murthy Karuturi, Patrick Boon Ooi Tan, Edison T. Liu and Qiang Yu. Pharmacologic disruption of Polycomb repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes & Development. 2007 21:1050. PMID: 17437993
  • Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, Shahab A, Yong HC, Fu Y, Weng Z, Liu J, Zhao XD, 4 Chew JL, Lee YL, Kuznetsov VA, Sung WK, Miller LD, Lim B, Liu ET, Yu Q, Ng HH, Ruan Y (2006). A global map of p53 transcription-factor binding sites in the human genome. Cell. 124(1):207-19. PMID:
2013201208522-1 A Novel Reagent For Gene-Drug Therapeutics
2013201208522-1 A Novel Reagent For Gene-Drug Therapeutics
2013201304198-3 Rasal2 is a biomarker associated with triple negative breast
cancer early relapse
2012201107036-4 STS1 (UBASH3B) is a novel druggable target for invasive
breast and prostate cancers
2010GIS/Z05818 A biomarker for rapamycin resposne
2009PCT/SG2009/000356 DZNep analogs as anti-cancer agents
2006PCT/SG2006/000350 Methods for Cancer Therapy and Stem Cell
2005PCT/SG2007/000058 Mothods for senstizing DNA Damage Response: A
Potential Target for Cancer Therapy
2005PCT/SG2006/000053 Methods for Assessing Suitability of Cancer
Patients for Treatment with Histone Deacetylase Inhibitors
2004PCT/SG2005/000223 Modulation of GSK-3 beta and Method of Treating
Proliferative Disorders